相关实验视频

Updated: Jan 8, 2026

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Ion Mobility-Mass Spectrometry Techniques for Determining the Structure and Mechanisms of Metal Ion Recognition and Redox Activity of Metal Binding Oligopeptides

Published on: September 7, 2019

在威尔逊病中重新利用黑激素的治疗潜力:解决铜过载和氧化还原失衡问题

Raviranjan Pandey¹, Arpan Narayan Roy¹, Sandip Sarkar²

¹Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur, West Bengal, 741246, India.

|December 17, 2025

概括

作为一种抗氧化剂的氨酸通过结合过多的铜和减少氧化应激,有效地治疗威尔逊病. 纳米颗粒封装进一步提高了这种遗传疾病的治疗效果和治疗效果.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
遗传学遗传学是一个

背景情况:

威尔逊病 (WD) 由ATP7B基因突变引起,导致铜积累和细胞损伤.
目前的WD治疗方法可化铜,但缺乏抗氧化特性,可能有毒.
氨酸,一种氨酸,具有抗氧化和潜在的金属化性质,与WD治疗有关.

研究的目的:

为了评估黑激素作为威尔逊病的治疗剂.
在WD模型中研究黑激素对铜诱导的氧化应激和细胞损伤的影响.
评估黑激素装载纳米囊在增强WD治疗中的潜力.

主要方法:

使用ATP7B-/-肝细胞进行体外研究,以评估ROS水平,亡和谷氨氧化.
异热定位热度计和分子动力学模拟,以分析Cu2+的结合亲和力和相互作用.
在斑马鱼胚胎和Caenorhabditis elegans WD模型中的体内研究.
开发和评估含有黑激素的聚合物纳米囊.

主要成果:

黑色素使铜诱导的ROS正常化,降低了肝细胞亡,并减轻了谷氨氧化.
黑色素证明了与现有疗法相比,具有合作性抗氧化剂-化优势.
在体内模型显示,在接受黑激素治疗后,氧化应激和铜负荷减少.
封装的黑激素呈现出十倍更长的半衰期和三倍增强的ROS清理功效.

结论:

Melatonin 通过结合铜化和抗氧化作用,为威尔逊病提供双重作用的治疗策略.
重用黑激素为WD提供了一种具有成本效益和临床安全的转化方法.
基于黑色素的疗法为治疗氧化还原和金属相关疾病提供了可通用的平台.

关键词:

在ATP7B中,它是ATP7B.铜铜铜铜铜铜药物重新定位是药物重新定位.黑色素是什么意思黑色素是什么意思威尔逊病是威尔逊病的一种疾病.

更多相关视频

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Positron Emission Tomography Using 64-Copper as a Tracer for the Study of Copper-Related Disorders

Published on: April 28, 2023

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

相关概念视频

Management of Insomnia

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...

Mania and Antimanic Drugs: Overview

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.